Paul Robinson is a Senior Staff Specialist and clinician researcher in the Department of Respiratory and Sleep Medicine at Queensland Children’s Hospital in Brisbane. He is a Conjoint Professor at the University of Queensland where he is the Deputy Director of the Children's Health and Environment Program. His research targets improved detection, and monitoring, of early lung disease using novel lung function and imaging tools across a number of important paediatric respiratory conditions. He leads international Multiple breath washout (MBW) standardisation work which has enabled its successful incorporation into international clinical trials. Ongoing research is funded by both national and international grants through strong collaborative networks established with leading researchers.

Michael is a paediatric respiratory physiotherapist with 20 year’s experience working with children who have acute and chronic respiratory conditions. Michael has spent the majority of his career as a clinician-researcher, completing research into the physiotherapy management of cystic fibrosis, neuromuscular disease as well as researching altered models of care delivery. Michael is also employed as an academic at Macquarie University in the Doctor of Physiotherapy Program. Michael is nearing completion of his own PhD investigating the use of telehealth in cystic fibrosis.

Professor Claire Wainwright is a paediatric respiratory physician and Co-Lead for cystic fibrosis services at the Queensland Children’s Hospital in Brisbane Australia which manages around 470 children with CF. Claire started her training in London and completed her training in paediatric respiratory medicine at the Royal Children’s Hospitals in Brisbane and Melbourne. Her research interests include clinical trials, development of lung disease in CF, airway microbiology, acute viral bronchiolitis, metabolic problems and patient reported outcomes in CF.

Professor Middleton is a Senior Staff Specialist in Respiratory & Sleep Medicine and CF Centre Director at Westmead Hospital and Clinical Professor at the University of Sydney. Over the last 20 years, he has developed a large clinic caring for people with CF and non-CF bronchiectasis and leads a diagnostic service for assessment of patients with bronchiectasis. Research interests include scientific and clinical studies of new CF therapies including the Phase III trial of triple CFTR modulator therapy (Elexacaftor / Tezacaftor / Ivacaftor) in people with CF published in the New England Journal of Medicine in 2019. Other interests include the effect of airways disease on women during pregnancy, leading a combined ERS TSANZ taskforce published in the European Respiratory Journal in 2020.

Annabelle is a paediatric and critical care physiotherapist at Te Whatu Ora Waitaha Canterbury, New Zealand. She has a special interest in Cystic Fibrosis, chronic cough and Bronchiectasis. She has currently been completing some research into exercise capacity and lung function following the introduction of Trikafta in New Zealand.

A/Prof Lucy Burr is an experienced respiratory physician, training supervisor and clinical trials researcher at Mater Health and Mater Research – University of Queensland (UQ). She has a PhD in bronchiectasis microbiology and is an Associate Professor and Deputy Head Medical School (Wellbeing and Success) at the University of Queensland. She is the Director of Respiratory, Sleep and Cystic Fibrosis medicine at the Mater Hospital, Brisbane.

Prof Jaffe is the John Beveridge Professor of Paediatrics and Head of the Discipline of Paediatrics and Child Health, School of Clinical Medicine at UNSW Sydney, and Paediatric Respiratory Consultant at Sydney Children’s Hospital. Prof Jaffe undertook his MD thesis in gene therapy for children with cystic fibrosis at Imperial College, London. Previously he was Consultant in Respiratory Research at Great Ormond Street Hospital for Children, London before moving to Australia in 2006. His main research interest is in translational research in children with cystic fibrosis and other rare childhood lung diseases, and is the Director of the miCF Research Laboratory for Precision Medicine in Cystic Fibrosis. He is the chair of the Asthma Australia Research Advisory Committee and Rare Voices Australia Scientific and Medical Advisory Committee.

Dr. Taylor-Cousar is a tenured Professor of Internal Medicine and Pediatrics at National Jewish Health where she cares for children with pulmonary disease and adults with Cystic Fibrosis. She was appointed as the Medical Director of Clinical Research Services for NJH in July 2017 and is currently the President of the Medical Staff. She is also the Co-Director of the Adult CF clinical program and the Director of CF Therapeutics Development Network research for the adult CF program. Her expertise is in clinical trial design and conduct, and therapeutic development for the treatment of CF lung disease. She is also actively evaluating the etiology and treatment of lung disease in orangutans (97% genetic homology with humans).